Navigation Links
Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine(TM) For Prostate Conditions With Start-Up of Phase 2 BPH Trial

BELLEVUE, Wash., Aug. 18 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

"Beyond Aptocine's late-stage development as a revolutionary treatment for solid tumors, we believe Aptocine also presents a new paradigm in treating benign neoplasms such as BPH," said LSO's President and CEO, Llew Keltner, M.D., Ph.D. "The Phase 2 BPH trial greatly widens the potential of Aptocine as a uniquely safe and effective targeted therapy."

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate. The most common clinical manifestation of BPH is lower urinary tract symptoms, including urinary frequency, urgency, nocturia, decreased and intermittent force of urine stream and sensation of incomplete bladder emptying. BPH is a disease of the aging male population with a dramatic increase in incidence after the age of 50 years. The American Urological Association estimates that BPH will affect approximately 50 percent of men between the ages of 51 and 60 and up to 90 percent of men over the age of 80.

The primary outcome measures of the Aptocine Phase 2 BPH trial are safety, according to number and severity of adverse events, and preliminary effectiveness, according to evaluation using the International Prostate Symptom Score (IPSS) and Bother Score (BS). Complete information on study protocol, investigators, and sites is available at with the identifier: NCT00918034 (

About Aptocine

Aptocine is a water-soluble drug targeted inside a tumor or other tissue by a small, single-use, disposable drug activator included with the drug. The drug activator contains a tiny array of LEDs that emits red light at a discrete frequency and intensity, for a fixed time period, to activate Aptocine and create a "treatment region" around the LED array. Constant illumination with the LEDs' low-intensity light can activate each molecule of Aptocine many times, resulting in a continuous supply of singlet oxygen molecules that can kill target tissues with minimal side effects through vascular closure and apoptosis. The Aptocine drug activator used in BPH is a linear LED array inside a standard catheter, providing a simple, easy-to-administer outpatient treatment. Administering physicians insert the catheter with LED array into the urethra, inject Aptocine intravenously, and then energize the drug activator. Aptocine advantages over existing therapies for BPH may include minimal side effects, safety, and repeatability.

About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Aptocine for solid tumors as well as benign neoplasms such as BPH. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in patients with BPH and in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology.

    Light Sciences Oncology, Inc.
    Llew Keltner, M.D., Ph.D.
    President & CEO

    Robert M. Littauer
    Vice President,
    Chief Financial Officer
    & Treasurer

Aptocine(TM) is a trademark of Light Sciences Oncology, Inc.

SOURCE Light Sciences Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EF Johnson Technologies, Inc. Highlights New Products at APCO 2009
2. August 2009 Mayo Clinic Womens HealthSource Highlights Health Care Dollars, Senses of Taste and Smell, and Emotional Eating
3. August 2009 Mayo Clinic Health Letter Highlights Herbal Supplements, Groin Rashes and Hand Arthritis
4. Lee County Schools "Lightens Up" by 2000 lbs and saves big
5. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
6. Lumie Reveals Light Levels Received In July Are As Low As A Winter's Day
7. Sunlight May Cause Rash in Autoimmune Disease
8. DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call
9. 11th Annual Light the Night Date Announced
10. Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A.
11. Smith & Nephew Highlights Advanced Wound Management Progress
Post Your Comments:
(Date:11/28/2015)... ... 2015 , ... Trying to relax on a couch can actually be uncomfortable, ... this design due to personal experience with a bad back," he said. , This ... as well as increases support. It also makes it easier to eat, do other ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the 21st ... not been an easy question to answer. Especially when the senior partners and lawyers ... share the same discipline around working long hours. , In addition to this ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South ... 750,000. The digital component is distributed nationally, through a vast social media strategy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... "Self Administration of High Viscosity Drugs" report ... has announced the addition of the "Self ... their offering. --> Research and Markets ... the "Self Administration of High Viscosity Drugs" ...
(Date:11/25/2015)... -- The total global healthcare industry is expected to grow at ... America has the highest projected growth at 12.7%, ... ), is second with growth projected at 11.5%. ... expenditure. In 2013-2014, total government funded healthcare was nearly 68%. ... 41.2% in 2013-2014. In real terms, out of pocket expenditure ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology: